Table 3.
Contrast-enhanced ultrasound imaging between benign and malignant non-mass-like lesions
| Parameter |
Pathology, n (%) |
Total | χ2 | P value | ||
| Benign | Malignant | |||||
| Later | 5 (17.86) | 0 (0.00) | 5 (9.80) | |||
| Enhancement time | Synchronous | 17 (60.71) | 9 (39.13) | 26 (51.98) | 10.270 | 0.006b |
| Earlier | 6 (21.43) | 14 (60.87) | 20 (39.22) | |||
| Hypo-enhanced | 7 (25.00) | 3 (13.04) | 10 (19.61) | |||
| Enhanced intensity | Iso-enhanced | 15 (53.57) | 4 (17.39) | 19 (37.25) | 12.140 | 0.002b |
| Hyper-enhanced | 6 (21.43) | 16 (69.57) | 22 (43.14) | |||
| Diffuse enhancement | 20 (71.43) | 18 (78.26) | 38 (74.51) | |||
| Enhancement direction | Centripetal | 4 (14.29) | 2 (8.70) | 6 (11.76) | 0.429 | 0.807 |
| Centrifugal | 4 (14.29) | 3 (13.04) | 7 (13.73) | |||
| Enhancement mode | Homogeneous | 22 (78.57) | 15 (65.22) | 37 (72.55) | 1.131 | 0.288 |
| Heterogeneous | 6 (21.43) | 8 (34.78) | 14 (27.45) | |||
| Lesion range | Without increase | 26 (92.86) | 8 (34.8) | 34 (66.67) | 22.288 | 0.000b |
| Increase | 2 (7.14) | 15 (65.2) | 17 (33.33) | |||
| Regression time | Later | 8 (28.57) | 11 (47.83) | 19 (37.25) | 2.921 | 0.232 |
| Synchronous | 15 (53.57) | 7 (30.43) | 22 (43.14) | |||
| Earlier | 5 (17.86) | 5 (21.74) | 10 (19.61) | |||
| Peripheral blood vessels | No | 21 (75) | 11 (47.83) | 32 (62.75) | 3.989 | 0.046a |
| Yes | 7 (25) | 12 (52.17) | 19 (37.25) | |||
a
P < 0.05;
b
P < 0.01.